Updated:
LENZ Therapeutics
LENZ Therapeutics is is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, focused on an eye drop to...
LENZ Therapeutics
LENZ Therapeutics is is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, focused on an eye drop to treat presbyopia and provide seamless vision for the vast majority of presbyopes.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Eef Schimmelpennink
President and CEO
Dan Chevallard
Chief Financial Officer
Shawn Olsson
Chief Commercial Officer
Marc Odrich
Chief Medical Officer
Sector focus
Frequently asked questions
Who runs investment decisions at LENZ Therapeutics?
LENZ Therapeutics is an operating pharmaceutical company, not a fund. Eef Schimmelpennink, as President and CEO, leads strategic allocation of capital toward commercialization of VIZZ. The board, chaired by Jeff George and including RA Capital's Zach Scheiner, approves major financial commitments. There is no separately managed investment portfolio disclosed.
How does LENZ Therapeutics generate revenue?
LENZ expects to generate revenue from US sales of VIZZ (aceclidine 1.44%), its only FDA-approved product, through a direct specialty sales force targeting eyecare professionals. The company has also stated an intention to pursue international licensing partnerships that would produce royalty or milestone income.
Is LENZ Therapeutics structured as a single family office or does it operate like a venture firm?
LENZ is neither. It operates as a commercial-stage pharmaceutical company publicly listed in the US following a merger with Graphite Bio. The firm does not invest in external startups or manage third-party capital; it deploys its own corporate resources exclusively toward the VIZZ franchise.
What is LENZ Therapeutics' relationship to RA Capital Management?
RA Capital Management is a significant institutional investor in LENZ Therapeutics. Zach Scheiner, a Principal at RA Capital, has served on LENZ's board of directors since October 2020, providing the firm with board-level influence typical of a lead life-sciences crossover investor.
Which therapeutic areas does LENZ Therapeutics target?
LENZ exclusively targets ophthalmology through its single product, VIZZ, for presbyopia. The company has not disclosed research programs in other therapeutic areas or additional ophthalmic indications, making it a narrow-moat bet on the presbyopia market.
Does LENZ maintain philanthropic structures, and how are they separated?
LENZ Therapeutics has not disclosed any controlled philanthropic foundations or donor-advised fund structures. The firm operates as a for-profit public company and does not describe charitable grantmaking activities as part of its corporate footprint.
What is LENZ Therapeutics' posture on co-investments alongside external life sciences investors?
LENZ does not act as a co-investor in other life sciences companies. As an operating entity, it uses its balance sheet to fund its own commercial activities. Investors seeking co-investment exposure to ophthalmology pre-revenue companies would look to its specialist board members' other portfolio activities, not to LENZ itself.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: